481 completed, 169 terminated, 115 recruiting, 89 unknown. 969 Phase 2, 149 Phase 1, 104 Phase 3.
Follow Gastroenteritis: new trials by email Literature Review of Gastroenteritis trials Research Report on Gastroenteritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of TRA16 Administered Orally in Patients With Enteric Hyperoxaluria (EH). TRA16, Placebo - Enteric Hyperoxaluria | Phase 2 | Not yet recruiting | Wuhan Kangfude Urolithiasis Research Institute Co., Ltd. | 30 | 2027-03-01 | 2026-10-13 |
| Oral N-acetylglucosamine in Crohn's Disease N-Acetylglucosamine (GlcNAc) - Crohns Disease | Phase 2 | Not yet recruiting | Johns Hopkins University | 40 | 2027-01-05 | 2026-11-05 |
| Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation Aquamin - Ulcerative Colitis, Ileal Pouch | Phase 2 | Recruiting | Muhammad N Aslam, MD | 52 | 2026-11-01 | 2026-11-02 |
| Nitazoxanide as Adjunct Therapy in Mild-to-Moderate Ulcerative Colitis Nitazoxanide (NTZ) - Ulcerative Colitis (UC) | Phase 2 / Phase 3 | Recruiting | Tanta University | 44 | 2026-10-25 | 2026-11-09 |
| A Study of SL-325 in Crohn's Disease Patients SL-325, Placebo - Crohn's Disease | Phase 2 | Recruiting | Shattuck Labs, Inc. | 232 | 2026-10-21 | 2026-11-03 |
| Patient Choice Between Antibiotics and Appendectomy in Uncomplicated Appendicitis (FRENCH 47 - ALACARTE) Shared decision-making, amoxicillin-clavulanate, Appendectomy - Acute Appendicitis | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 560 | 2026-10-01 | 2026-10-05 |
| Vancomycin Efficacy in Response to Dysbiosis in Atypical Colitis Oral Vancomycin - Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC) | Phase 2 | Not yet recruiting | Tampere University Hospital | 140 | 2026-10-01 | 2026-09-10 |
| A Phase 2, Placebo-Controlled Study of Oral RXC008 for Crohn's Strictures High Dose, Low Dose, Placebo - Strictures Due to Crohn's Disease | Phase 2 | Not yet recruiting | Redx Pharma Ltd | 180 | 2026-10-01 | 2026-09-22 |
| A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis Upadacitinib 30mg Dose, Upadacitinib Matching Placebo - EoE, Eosinophilic Esophagitis | Phase 2 | Recruiting | University of North Carolina, Chapel Hill | 52 | 2026-09-30 | 2026-10-06 |
| A Study of AC-101 Tablets in Patients With Ulcerative Colitis AC-101, Placebo - Ulcerative Colitis (UC) | Phase 2 | Recruiting | Accro Bioscience (Suzhou) Limited | 153 | 2026-09-10 | 2026-10-28 |
| Hyperbaric Oxygen Therapy for Perianal Fistulizing Crohn's Disease Not Responsive or Intolerant to Conventional Care: HYPNOTIC Pilot Study Oxygen Gas for Inhalation, Standard of care - Inflammatory Bowel Disease (IBD), Crohn Disease | Phase 1 / Phase 2 | Not yet recruiting | University of British Columbia | 54 | 2026-09-01 | 2026-08-26 |
| A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis PALI-2108, Placebo - Ulcerative Colitis (UC), Severe Ulcerative Colitis | Phase 2 | Recruiting | Palisade Bio | 204 | 2026-08-28 | 2026-10-21 |
| Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer Vedolizumab, Placebo - IrAE, Immune-related Adverse Event | Phase 2 / Phase 3 | Recruiting | AHS Cancer Control Alberta | 36 | 2026-08-13 | 2026-08-27 |
| A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease Zasocitinib - Crohn's Disease | Phase 2 | Recruiting | Takeda | 20 | 2026-08-13 | 2026-08-24 |
| Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial) Modafinil, Placebo - Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Chronic Fatigue | Phase 2 / Phase 3 | Recruiting | Radboud University Medical Center | 60 | 2026-08-03 | 2026-09-14 |
| A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of PTT-621 in Patients With Moderately to Severely Active Ulcerative Colitis PTT-621 Tablets - Ulcerative Colitis (UC) | Phase 2 | Not yet recruiting | Pyrotech Therapeutics, Inc. | 40 | 2026-08-01 | 2026-08-07 |
| Seaweed Extract (Fucoidan) for Gut Inflammation in Ulcerative Colitis Low molecular weight fucoidan and standard care, Placebo and standard of care - Ulcerative Colitis (UC) | Phase 1 / Phase 2 | Enrolling by invitation | Allama Iqbal Medical College | 90 | 2026-08-01 | 2026-08-26 |
| Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis Risankizumab, Trosunilimab, ABBV-701 - Crohn's Disease, Ulcerative Colitis | Phase 2 | Recruiting | AbbVie | 2000 | 2026-07-31 | 2026-10-27 |
| HB-adMSCs for the Treatment of Crohn's Disease HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells, 0.9% sodium chloride - Crohn Disease (CD) | Phase 2 | Recruiting | Hope Biosciences Research Foundation | 46 | 2026-07-14 | 2026-08-06 |
| A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease H021 Enteric-coated Tablets Low-dose Group, H021 Enteric-coated Tablets High-dose Group, Placebo Group - Crohn's Disease | Phase 2 | Not yet recruiting | Jiangsu Carephar Pharmaceutical Co., Ltd. | 156 | 2026-07-12 | 2026-06-30 |
Showing 20 of 969. Sign in to see all of them.
Colitis, Ulcerative (345) · Crohn Disease (315) · Inflammatory Bowel Diseases (169) · Mucositis (74) · Eosinophilic Esophagitis (50) · Colitis (38) · Enterocolitis, Necrotizing (28) · Esophagitis (26) · Dysentery, Bacillary (23) · Head and Neck Neoplasms (20) · Stomatitis (20) · Diarrhea (18) · Appendicitis (16) · Gastrointestinal Diseases (15)
Digestive System Diseases (956) · Gastrointestinal Diseases (954) · Intestinal Diseases (788) · Inflammatory Bowel Diseases (498) · Colonic Diseases (373) · Colitis (328) · Pathological Conditions, Signs and Symptoms (116) · Immune System Diseases (86) · Infections (82) · Hemic and Lymphatic Diseases (81) · Stomatognathic Diseases (74) · Mouth Diseases (73) · Esophageal Diseases (70) · Hematologic Diseases (70)
Fecal Microbiota Transplantation (31) · Mesalamine (24) · Budesonide (14) · Metronidazole (14) · vedolizumab (14) · Saline Solution (13) · Vancomycin (12) · Adalimumab (11) · etrasimod (11) · Infliximab (10) · Sodium Chloride (9) · Cyclophosphamide (8) · Ustekinumab (8) · mirikizumab (7) · visilizumab (7)
Pfizer (20) · GlaxoSmithKline (15) · Janssen Research & Development, LLC (15) · AbbVie (14) · Children's Hospital Medical Center, Cincinnati (13) · National Institute of Allergy and Infectious Diseases (NIAID) (12) · Sanofi (11) · Tanta University (11) · AstraZeneca (10) · Bristol-Myers Squibb (10) · Mayo Clinic (10) · Takeda (10) · Amgen (9) · Boehringer Ingelheim (9) · Novartis Pharmaceuticals (9)
United States (481) · Canada (187) · Poland (173) · Germany (169) · France (141) · Hungary (134) · Belgium (132) · Italy (125) · United Kingdom (119) · Czechia (112) · Netherlands (111) · Spain (103) · Israel (100) · Australia (93) · Japan (82)
Dina Kao, MD (5) · Amy Lightner, MD (4)
PMID 30721964, PMID 40357993, PMID 21871249, PMID 22325170, PMID 23188075, PMID 26893500, PMID 28209624, PMID 29247068, PMID 30113844, PMID 30739254, PMID 31982148, PMID 38863178, PMID 39575597, PMID 39778975, PMID 41359652, PMID 10440607, PMID 11171619, PMID 11427329, PMID 11692292, PMID 12809830, PMID 15017618, PMID 15057287, PMID 15234753, PMID 16984503, PMID 17222320, PMID 17382603, PMID 17560413, PMID 17636753, PMID 17920064, PMID 17975182, PMID 18325386, PMID 18468541, PMID 18623174, PMID 18706417, PMID 18809665, PMID 18829392, PMID 18829790, PMID 18952896, PMID 18973181, PMID 19145731, PMID 19208097, PMID 19302707, PMID 19358184, PMID 19421322, PMID 19505878, PMID 19634161, PMID 19714757, PMID 19828470, PMID 19842970, PMID 19885903
2023 (24), 2017 (18), 2018 (15), 2016 (13), 2025 (13), 2014 (10), 2019 (10), 2015 (8), 2008 (4), 2009 (4), 2005 (2), P30CA015083 (2), U54AI117804 (2), UL1RR024150 (2), 1UG3DE030401-01 (1)